View ValuationValeo Pharma 향후 성장Future 기준 점검 2/6Valeo Pharma의 수익이 증가할 것으로 예상됨입니다.핵심 정보n/a이익 성장률n/aEPS 성장률Pharmaceuticals 이익 성장14.4%매출 성장률20.9%향후 자기자본이익률n/a애널리스트 커버리지Low마지막 업데이트17 Jun 2024최근 향후 성장 업데이트업데이트 없음모든 업데이트 보기Recent updates공시 • Feb 07Xediton Pharmaceuticals Inc. completed the acquisition of Valeo Pharma Inc. (OTCPK:VPHI.F).Xediton Pharmaceuticals Inc. entered into a definitive agreement to acquire Valeo Pharma Inc. (OTCPK:VPHI.F) on January 17, 2025. Cheryl Reicin of Mintz LLP acted as legal advisor for Xediton Pharmaceuticals and Tushara Weerasooriya, Emile Catimel-Marchand and Eric Vallieres of McMillan LLPacted as legal advisors for Valeo Pharma Inc. The court appointed Ernst & Young Inc. monitor in the CCAA proceedings. Xediton Pharmaceuticals Inc. completed the acquisition of Valeo Pharma Inc. (OTCPK:VPHI.F) on February 5, 2025. The Transaction was approved by the Quebec Superior Court on February 4, 2025 pursuant to an approval and reverse vesting order. Board of Directors of Valeo Pharma approved the transaction.공시 • Sep 09Valeo Pharma Inc. to Report Q3, 2024 Results on Sep 12, 2024Valeo Pharma Inc. announced that they will report Q3, 2024 results After-Market on Sep 12, 2024공시 • Aug 07Valeo Pharma Inc. Announces Board ChangesValeo Pharma Inc. announced Mr. Steve Saviuk will remain on the company’s board of directors and assume the role of Chairman. Mr. Richard J. MacKay will step down from his role of chairman of the board and will remain a board member.공시 • Jun 18Valeo Pharma Inc. Appoints Al Moghaddam as Chief Development Officer and Consequently Steps Down from its Board of DirectorsValeo Pharma Inc. announced that Mr. Al Moghaddam has been appointed to the newly created role of Chief Development Officer (CDO) and consequently he is stepping down from the Company's Board of Directors. As Valeo's new CDO, Mr. Moghaddam will lead the design and implementation of strategies to identify and negotiate with financial parties with a view to strengthening the Company's capital structure in order to finance the future growth and development of the Company. He will work directly with the senior management team to plan, review, and revise the company's development programs. Mr. Moghaddam will also support the development and growth of the business through building relationships in the industry, identifying both product and M&A opportunities. Mr. Moghaddam is a customer centric transformational life sciences leader with over 25 years of global experience. His work experience spans from large multinationals through to early-stage companies and he has held leadership positions within pharma, medical device, med-tech, and consumer markets. He is a strong visionary, process driven leader, able to craft a vision and motivate teams to achieve superior results and recognized by such companies as Allergan, Bristol Myers Squibb, Teva & Pharmascience for outstanding performance in creating value. Al has cross functional experience in product life cycle management, sales, BD&L, market access, marketing, finance & M&A.공시 • Jun 06Valeo Pharma Inc. to Report Q2, 2024 Results on Jun 13, 2024Valeo Pharma Inc. announced that they will report Q2, 2024 results After-Market on Jun 13, 2024공시 • Mar 22Valeo Pharma Inc. Announces Appointment of Al Moghaddam to Board of DirectorsValeo Pharma Inc. announced that Mr. Al Moghaddam has joined the Company's Board of Directors. Mr. Moghaddam is a customer centric transformational life sciences leader with over 25 years of global experience. His work experience spans from large multinationals through to early-stage companies and he has held leadership positions within pharma, medical device, med-tech, and consumer markets. He is a strong visionary, process driven leader, able to craft a vision and motivate teams to achieve superior results and recognized by such companies as Allergan, Bristol Myers Squibb, Teva & Pharmascience for outstanding performance in creating value. Al has cross functional experience in product life cycle management, sales, BD&L, market access, marketing, finance & M&A.공시 • Mar 08Valeo Pharma Inc. to Report Q1, 2024 Results on Mar 14, 2024Valeo Pharma Inc. announced that they will report Q1, 2024 results After-Market on Mar 14, 2024공시 • Feb 27Valeo Pharma Inc., Annual General Meeting, Apr 25, 2024Valeo Pharma Inc., Annual General Meeting, Apr 25, 2024.공시 • Feb 13Valeo Pharma Inc. Announces Board ChangesValeo Pharma Inc. announced that Messrs. Robert Raich and Charles Bisaillon have joined the Company's Board of Directors and that Messrs. Michel Trudeau, Stuart Fowler, Didier Leconte and Ms. Tamara Close have all resigned from its Board of Directors. More about Robert Raich; Prior to establishing RaichLegal Inc, Robert Raich was a senior partner at Spiegel Sohmer Inc., a Montreal firm specializing in taxation law, where he served as managing partner for over 25 years. His areas of expertise include taxation advice for real estate transactions, advice to both purchasers and vendors in acquisitions and sales of businesses, corporate reorganizations, venture capital financing and charitable planning. Mr. Raich graduated from McGill University and was called to the Barreau du Quebec in 1976. He has been recognized on several occasions as one of the Best Lawyers in Canada in the fields of Taxation law and Law of Estates and Trusts in Canada and has been a frequent guest lecturer at McGill University Faculty of Law and tax conferences. More about Charles Bisaillon; Charles Bisaillon is an entrepreneurial-minded leader who loves rapidly scaling organizations in both wholesale & direct-to-consumer channels. Charles is currently President and owner of Airtek Ltée, a leading Canadian manufacturing company, established in Montreal Quebec since 1970. Charles is also the Chief Financial Officer Groupe J.B a residential, commercial & institutional construction company. Mr. Bisaillon graduated from l'École des sciences de la gestion, UQAM. He is a chartered professional accountant of Canada (CPA Canada).공시 • Jan 23Valeo Pharma Inc. to Report Q4, 2023 Results on Jan 29, 2024Valeo Pharma Inc. announced that they will report Q4, 2023 results After-Market on Jan 29, 2024공시 • Nov 21Valeo Pharma Inc. Announces Chief Financial Officer ChangesValeo Pharma Inc. announced the appointment of Mr. Pascal Tougas to the position of Chief Financial Officer, effective November 20, 2023. Joining the Valeo leadership team, Mr. Tougas will succeed Luc Mainville, who is leaving the Company after 5 years to pursue other ventures. Pascal is a seasoned senior pharmaceutical executive with a strong finance profile. With a passion for driving value in organizations, Pascal has a track record of collaboration, forward strategic thinking, operational and financial business acumen, and execution. Pascal spent 11 years at Sanofi Canada in roles of increasing responsibility where he served as Country Head, Trade and Revenue Management, Chief Financial Officer Canada interim and Director Controlling and Operations Canada amongst others. Pascal holds a bachelor's degree in business administration from the HEC Montreal and a CPA designation.공시 • Nov 08Valeo Pharma Inc. Announces Appointment of Mr. Richard Lajoie to Board of DirectorsValeo Pharma Inc. announced that Mr. Richard Lajoie has joined the Company's Board of Directors and that Ms. Maureen C. Brennan has retired from its Board of Directors. ichard Lajoie has been recognized over the last 24 years as an inspirational and creative leader with a strong capacity to build high performing teams. Richard was President of Bausch Health, Canada from 2017 to 2021 before being promoted to President Ortho Dermatologics US based in New Jersey. He has led innovative business model transformations, many new launches and completed successful business development deals. Prior to Bausch Health, Richard spent 12 years with Novartis Pharmaceuticals in roles of increasing responsibility (Sales, Marketing, Government Affairs and Medical) located in Montreal, Calgary and Copenhagen where he led Denmark, Norway and Iceland as General Manager for Novartis Oncology.공시 • Sep 08Valeo Pharma Inc. to Report Q3, 2023 Results on Sep 13, 2023Valeo Pharma Inc. announced that they will report Q3, 2023 results After-Market on Sep 13, 2023공시 • Sep 01Valeo Pharma Inc. announced that it has received CAD 4.499999 million in funding from Investissement QuébecValeo Pharma Inc. announced a non-brokered private placement of 13,999,997 units of the company at a price of CAD 0.28 per unit for gross proceeds of CAD 3,919,999 and entered into a loan agreement with a related party for a principal amount of CAD 580,000 bearing annual interest at a rate of 12%; for aggregate total gross proceeds of CAD 4,499,999 on August 31, 2023. The transaction included participation from Investissement Québec for CAD 2 million and insiders for CAD 1,421,000. Each unit consist of one class A share of the company and one-half share purchase warrant of the company. Each full warrant entitles the holder to purchase one share in the capital of the company at the price of CAD 0.35 per warrant share for a period of 60 months from the closing date of the transaction. In the event that the daily volume weighted average trading price of the shares over any ten consecutive trading days is greater or equal to CAD 0.70, the company may give notice to the warrant holder, at any time after the first 12 months following the closing, that all outstanding warrants must be exercised within a period of 30 days from the date of receipt of the notice, failing which the warrants will automatically expire. The common shares and the warrants are subject to a statutory 4 month hold period under the applicable securities laws.공시 • Jun 23Valeo Pharma Inc. Announces Board AppointmentsValeo Pharma Inc. announced that Ms. Tamara Close and Mr. Didier Leconte have joined its Board of Directors. Following the appointment of Ms. Close and Mr. Leconte, Valeo's Board of Directors is now comprised of 8 Directors, 5 of whom are independent. Ms. Close is a senior investment and Environmental, Social and Governance (ESG) professional with over 25 years of experience in capital markets, with roles spanning sell-side trading and institutional sales to buy-side research, risk management and strategy. She is the founder and managing partner of Close Group Consulting, an independent, boutique ESG advisory firm headquartered in Montreal, with offices in Toronto, Boston, and London (UK). Tamara is a sought-after speaker and regularly publishes ESG thought leadership and research. Ms. Close holds an M.Sc. Finance from Concordia University with a B.A. Economics from McGill University and is a Chartered Financial Analyst (CFA). Mr. Didier Leconte is a highly experienced investor and Canadian life sciences leader. He has deep commercial experience in Canada and Québec's technology transfer and investment arenas. With a strong dedication to the development of Québec's and Canada's life sciences industries, Didier served as Vice-president, Life Science & Technology for Investissement Quebec and Vice-president Life Sciences at Fonds de solidarité FTQ. Mr. Leconte holds a MBA, Technology Management & Innovation from the Université du Québec à Montréal, a certification in governance from Université Laval and an engineering degree in Material Sciences from École d'ingénieurs Sup Galilée, Institut Galilée, Université Sorbonne Paris Nord.공시 • Jun 09Valeo Pharma Inc. to Report Q2, 2023 Results on Jun 13, 2023Valeo Pharma Inc. announced that they will report Q2, 2023 results After-Market on Jun 13, 2023공시 • Feb 08Valeo Pharma Obtains Public Reimbursement for Onstryv in QuebecValeo Pharma Inc. announced that Onstryv (safinamide) for the treatment of patients suffering from Parkinson's disease, is now listed for public reimbursement on the Public Prescription Drug Insurance Plan of the Quebec Régie de l'assurance maladie du Québec ("RAMQ"), effective February 1, 2023. Onstryv® is approved by Health Canada as an add-on therapy to a regimen that includes levodopa for the treatment of the signs and symptoms of idiopathic Parkinson's Disease in patients experiencing "off" episodes. Onstryvâ is a prescription medication available at pharmacies across Canada in 50mg and 100mg tablets. Parkinson's Disease is a progressive neurological disease involving the loss of dopamine producing neurons in the brain. While tremors are the best known symptom, Parkinson's Disease also causes other symptoms including slowed movement, rigid muscles, impaired posture and balance, speech and writing difficulties. On a per capita basis, Canada has amongst the higher incidences of Parkinson's Disease in the world and the number of patients is expected to grow significantly over the next thirty years as the median population age increases. Safinamide, known as Onstryv® in Canada and Xadago® in the rest of the world, is a chemical entity with a unique mode of action including selective and reversible MAO-B inhibition. Clinical trials have established its efficacy in controlling motor symptoms and motor complications in the short term, maintaining this effect over 2 years. Results from 24 month double-blind controlled studies suggest that safinamide shows statistically significant effects on motor fluctuations (ON/OFF time) without increasing the risk of developing troublesome dyskinesia. Onstryv® is a once-daily dose and has no diet restrictions due to its high MAO-B/MAO-A selectivity.공시 • Jan 27Valeo Pharma Announces Filing of New Drug Submission-Covid 19 with Health Canada for Sabizabulin for the Treatment of Hospitalized Covid-19 PatientsValeo Pharma Inc. announced that Health Canada has accepted for review Veru's New Drug Submission ("NDS-CV") for sabizabulin for COVID-19. Sabizabulin is a novel dual antiviral and anti-inflammatory agent being developed for the treatment of hospitalized moderate to severe COVID-19 adult patients at high risk for acute respiratory distress syndrome (ARDS) and death. The Phase 3 COVID-19 clinical trial of sabizabulin was a double-blind, randomized, placebo controlled trial conducted in 204 hospitalized COVID-19 patients with moderate to severe COVID-19 (= WHO 4-supplemental oxygen) at high risk for ARDS and death. The primary endpoint was the proportion of deaths by Day 60. Patients in both treatment groups were allowed to receive standard of care treatment, including remdesivir, dexamethasone, anti-IL6 receptor antibodies and JAK inhibitors. Based on a planned interim analysis of the first 150 patients randomized, the Independent Data Monitoring Committee unanimously recommended to halt the study early for clear clinical efficacy and no safety concerns were identified. Treatment with sabizabulin 9 mg once daily, an oral, first-in-class, new chemical entity, microtubule disruptor that has dual anti-inflammatory and antiviral properties, resulted in a clinically meaningful and statistically significant 55.2% relative reduction in deaths compared to placebo. The results of the interim analysis were published in The New England Journal of Medicine (NEJM) Evidence. In the final analysis of all 204 patients, sabizabulin demonstrated a statistically significant 51.6% relative reduction in deaths compared to placebo. Sabizabulin was well tolerated. Valeo previously announced in September 2022 that Veru and Valeo had entered into an agreement under which Valeo is the commercial partner for Veru's product candidate sabizabulin for COVID-19 in Canada.공시 • Jan 26Valeo Pharma Inc. to Report Q4, 2022 Results on Jan 30, 2023Valeo Pharma Inc. announced that they will report Q4, 2022 results at 4:00 PM, US Eastern Standard Time on Jan 30, 2023이익 및 매출 성장 예측OTCPK:VPHI.F - 애널리스트 향후 추정치 및 과거 재무 데이터 (CAD Millions)날짜매출이익자유현금흐름영업현금흐름평균 애널리스트 수10/31/202570N/AN/AN/A110/31/202458N/AN/AN/A17/31/202453-32-7-4N/A4/30/202455-30-10-6N/A1/31/202454-28-8-3N/A10/31/202354-28-21-16N/A7/31/202353-28-20-24N/A4/30/202345-27-32-25N/A1/31/202337-26-37-31N/A10/31/202228-26-35-29N/A7/31/202218-24-33-20N/A4/30/202218-22-25-23N/A1/31/202216-18-22-19N/A10/31/202114-14-16-12N/A7/31/202112-9-14-12N/A4/30/20218-7-10-7N/A1/31/20218-5-8-6N/A10/31/20207-5-7-5N/A7/31/20207-4-5-4N/A4/30/20208-2-5-4N/A1/31/20206-4-5-4N/A10/31/20197-4-3-2N/A7/31/20197-3-3-2N/A4/30/20197-3-2-2N/A1/31/20196-3-2-1N/A10/31/20184-2-2-1N/A7/31/20183-3-1-1N/A10/31/20171-4N/A-1N/A10/31/20161-1N/A-2N/A더 보기애널리스트 향후 성장 전망수입 대 저축률: VPHI.F 의 예상 수익 증가율이 절약률(2.6%)보다 높은지 판단하기에는 데이터가 부족합니다.수익 vs 시장: VPHI.F 의 수익이 US 시장보다 빠르게 성장할 것으로 예상되는지 판단하기에는 데이터가 부족합니다.고성장 수익: VPHI.F 의 수익이 향후 3년 동안 상당히 증가할 것으로 예상되는지 판단하기에는 데이터가 부족합니다.수익 대 시장: VPHI.F 의 수익(연간 20.9%)이 US 시장(연간 11.7%)보다 빠르게 성장할 것으로 예상됩니다.고성장 매출: VPHI.F 의 수익(연간 20.9%)은 연간 20%보다 빠르게 증가할 것으로 예상됩니다.주당순이익 성장 예측향후 자기자본이익률미래 ROE: VPHI.F의 자본 수익률이 3년 후 높을 것으로 예상되는지 판단하기에 데이터가 부족합니다.성장 기업 찾아보기7D1Y7D1Y7D1YPharmaceuticals-biotech 산업의 고성장 기업.View Past Performance기업 분석 및 재무 데이터 상태데이터최종 업데이트 (UTC 시간)기업 분석2024/11/26 21:01종가2024/08/29 00:00수익2024/07/31연간 수익2023/10/31데이터 소스당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.패키지데이터기간미국 소스 예시 *기업 재무제표10년손익계산서현금흐름표대차대조표SEC 양식 10-KSEC 양식 10-Q분석가 컨센서스 추정치+3년재무 예측분석가 목표주가분석가 리서치 보고서Blue Matrix시장 가격30년주가배당, 분할 및 기타 조치ICE 시장 데이터SEC 양식 S-1지분 구조10년주요 주주내부자 거래SEC 양식 4SEC 양식 13D경영진10년리더십 팀이사회SEC 양식 10-KSEC 양식 DEF 14A주요 개발10년회사 공시SEC 양식 8-K* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.분석 모델 및 스노우플레이크이 보고서를 생성하는 데 사용된 분석 모델에 대한 자세한 내용은 당사의 Github 페이지에서 확인하실 수 있습니다. 또한 보고서 활용 방법에 대한 가이드와 YouTube 튜토리얼도 제공합니다.Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.산업 및 섹터 지표산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.분석가 소스Valeo Pharma Inc.는 1명의 분석가가 다루고 있습니다. 이 중 1명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.분석가기관Scott McAuleyParadigm Capital, Inc.
공시 • Feb 07Xediton Pharmaceuticals Inc. completed the acquisition of Valeo Pharma Inc. (OTCPK:VPHI.F).Xediton Pharmaceuticals Inc. entered into a definitive agreement to acquire Valeo Pharma Inc. (OTCPK:VPHI.F) on January 17, 2025. Cheryl Reicin of Mintz LLP acted as legal advisor for Xediton Pharmaceuticals and Tushara Weerasooriya, Emile Catimel-Marchand and Eric Vallieres of McMillan LLPacted as legal advisors for Valeo Pharma Inc. The court appointed Ernst & Young Inc. monitor in the CCAA proceedings. Xediton Pharmaceuticals Inc. completed the acquisition of Valeo Pharma Inc. (OTCPK:VPHI.F) on February 5, 2025. The Transaction was approved by the Quebec Superior Court on February 4, 2025 pursuant to an approval and reverse vesting order. Board of Directors of Valeo Pharma approved the transaction.
공시 • Sep 09Valeo Pharma Inc. to Report Q3, 2024 Results on Sep 12, 2024Valeo Pharma Inc. announced that they will report Q3, 2024 results After-Market on Sep 12, 2024
공시 • Aug 07Valeo Pharma Inc. Announces Board ChangesValeo Pharma Inc. announced Mr. Steve Saviuk will remain on the company’s board of directors and assume the role of Chairman. Mr. Richard J. MacKay will step down from his role of chairman of the board and will remain a board member.
공시 • Jun 18Valeo Pharma Inc. Appoints Al Moghaddam as Chief Development Officer and Consequently Steps Down from its Board of DirectorsValeo Pharma Inc. announced that Mr. Al Moghaddam has been appointed to the newly created role of Chief Development Officer (CDO) and consequently he is stepping down from the Company's Board of Directors. As Valeo's new CDO, Mr. Moghaddam will lead the design and implementation of strategies to identify and negotiate with financial parties with a view to strengthening the Company's capital structure in order to finance the future growth and development of the Company. He will work directly with the senior management team to plan, review, and revise the company's development programs. Mr. Moghaddam will also support the development and growth of the business through building relationships in the industry, identifying both product and M&A opportunities. Mr. Moghaddam is a customer centric transformational life sciences leader with over 25 years of global experience. His work experience spans from large multinationals through to early-stage companies and he has held leadership positions within pharma, medical device, med-tech, and consumer markets. He is a strong visionary, process driven leader, able to craft a vision and motivate teams to achieve superior results and recognized by such companies as Allergan, Bristol Myers Squibb, Teva & Pharmascience for outstanding performance in creating value. Al has cross functional experience in product life cycle management, sales, BD&L, market access, marketing, finance & M&A.
공시 • Jun 06Valeo Pharma Inc. to Report Q2, 2024 Results on Jun 13, 2024Valeo Pharma Inc. announced that they will report Q2, 2024 results After-Market on Jun 13, 2024
공시 • Mar 22Valeo Pharma Inc. Announces Appointment of Al Moghaddam to Board of DirectorsValeo Pharma Inc. announced that Mr. Al Moghaddam has joined the Company's Board of Directors. Mr. Moghaddam is a customer centric transformational life sciences leader with over 25 years of global experience. His work experience spans from large multinationals through to early-stage companies and he has held leadership positions within pharma, medical device, med-tech, and consumer markets. He is a strong visionary, process driven leader, able to craft a vision and motivate teams to achieve superior results and recognized by such companies as Allergan, Bristol Myers Squibb, Teva & Pharmascience for outstanding performance in creating value. Al has cross functional experience in product life cycle management, sales, BD&L, market access, marketing, finance & M&A.
공시 • Mar 08Valeo Pharma Inc. to Report Q1, 2024 Results on Mar 14, 2024Valeo Pharma Inc. announced that they will report Q1, 2024 results After-Market on Mar 14, 2024
공시 • Feb 27Valeo Pharma Inc., Annual General Meeting, Apr 25, 2024Valeo Pharma Inc., Annual General Meeting, Apr 25, 2024.
공시 • Feb 13Valeo Pharma Inc. Announces Board ChangesValeo Pharma Inc. announced that Messrs. Robert Raich and Charles Bisaillon have joined the Company's Board of Directors and that Messrs. Michel Trudeau, Stuart Fowler, Didier Leconte and Ms. Tamara Close have all resigned from its Board of Directors. More about Robert Raich; Prior to establishing RaichLegal Inc, Robert Raich was a senior partner at Spiegel Sohmer Inc., a Montreal firm specializing in taxation law, where he served as managing partner for over 25 years. His areas of expertise include taxation advice for real estate transactions, advice to both purchasers and vendors in acquisitions and sales of businesses, corporate reorganizations, venture capital financing and charitable planning. Mr. Raich graduated from McGill University and was called to the Barreau du Quebec in 1976. He has been recognized on several occasions as one of the Best Lawyers in Canada in the fields of Taxation law and Law of Estates and Trusts in Canada and has been a frequent guest lecturer at McGill University Faculty of Law and tax conferences. More about Charles Bisaillon; Charles Bisaillon is an entrepreneurial-minded leader who loves rapidly scaling organizations in both wholesale & direct-to-consumer channels. Charles is currently President and owner of Airtek Ltée, a leading Canadian manufacturing company, established in Montreal Quebec since 1970. Charles is also the Chief Financial Officer Groupe J.B a residential, commercial & institutional construction company. Mr. Bisaillon graduated from l'École des sciences de la gestion, UQAM. He is a chartered professional accountant of Canada (CPA Canada).
공시 • Jan 23Valeo Pharma Inc. to Report Q4, 2023 Results on Jan 29, 2024Valeo Pharma Inc. announced that they will report Q4, 2023 results After-Market on Jan 29, 2024
공시 • Nov 21Valeo Pharma Inc. Announces Chief Financial Officer ChangesValeo Pharma Inc. announced the appointment of Mr. Pascal Tougas to the position of Chief Financial Officer, effective November 20, 2023. Joining the Valeo leadership team, Mr. Tougas will succeed Luc Mainville, who is leaving the Company after 5 years to pursue other ventures. Pascal is a seasoned senior pharmaceutical executive with a strong finance profile. With a passion for driving value in organizations, Pascal has a track record of collaboration, forward strategic thinking, operational and financial business acumen, and execution. Pascal spent 11 years at Sanofi Canada in roles of increasing responsibility where he served as Country Head, Trade and Revenue Management, Chief Financial Officer Canada interim and Director Controlling and Operations Canada amongst others. Pascal holds a bachelor's degree in business administration from the HEC Montreal and a CPA designation.
공시 • Nov 08Valeo Pharma Inc. Announces Appointment of Mr. Richard Lajoie to Board of DirectorsValeo Pharma Inc. announced that Mr. Richard Lajoie has joined the Company's Board of Directors and that Ms. Maureen C. Brennan has retired from its Board of Directors. ichard Lajoie has been recognized over the last 24 years as an inspirational and creative leader with a strong capacity to build high performing teams. Richard was President of Bausch Health, Canada from 2017 to 2021 before being promoted to President Ortho Dermatologics US based in New Jersey. He has led innovative business model transformations, many new launches and completed successful business development deals. Prior to Bausch Health, Richard spent 12 years with Novartis Pharmaceuticals in roles of increasing responsibility (Sales, Marketing, Government Affairs and Medical) located in Montreal, Calgary and Copenhagen where he led Denmark, Norway and Iceland as General Manager for Novartis Oncology.
공시 • Sep 08Valeo Pharma Inc. to Report Q3, 2023 Results on Sep 13, 2023Valeo Pharma Inc. announced that they will report Q3, 2023 results After-Market on Sep 13, 2023
공시 • Sep 01Valeo Pharma Inc. announced that it has received CAD 4.499999 million in funding from Investissement QuébecValeo Pharma Inc. announced a non-brokered private placement of 13,999,997 units of the company at a price of CAD 0.28 per unit for gross proceeds of CAD 3,919,999 and entered into a loan agreement with a related party for a principal amount of CAD 580,000 bearing annual interest at a rate of 12%; for aggregate total gross proceeds of CAD 4,499,999 on August 31, 2023. The transaction included participation from Investissement Québec for CAD 2 million and insiders for CAD 1,421,000. Each unit consist of one class A share of the company and one-half share purchase warrant of the company. Each full warrant entitles the holder to purchase one share in the capital of the company at the price of CAD 0.35 per warrant share for a period of 60 months from the closing date of the transaction. In the event that the daily volume weighted average trading price of the shares over any ten consecutive trading days is greater or equal to CAD 0.70, the company may give notice to the warrant holder, at any time after the first 12 months following the closing, that all outstanding warrants must be exercised within a period of 30 days from the date of receipt of the notice, failing which the warrants will automatically expire. The common shares and the warrants are subject to a statutory 4 month hold period under the applicable securities laws.
공시 • Jun 23Valeo Pharma Inc. Announces Board AppointmentsValeo Pharma Inc. announced that Ms. Tamara Close and Mr. Didier Leconte have joined its Board of Directors. Following the appointment of Ms. Close and Mr. Leconte, Valeo's Board of Directors is now comprised of 8 Directors, 5 of whom are independent. Ms. Close is a senior investment and Environmental, Social and Governance (ESG) professional with over 25 years of experience in capital markets, with roles spanning sell-side trading and institutional sales to buy-side research, risk management and strategy. She is the founder and managing partner of Close Group Consulting, an independent, boutique ESG advisory firm headquartered in Montreal, with offices in Toronto, Boston, and London (UK). Tamara is a sought-after speaker and regularly publishes ESG thought leadership and research. Ms. Close holds an M.Sc. Finance from Concordia University with a B.A. Economics from McGill University and is a Chartered Financial Analyst (CFA). Mr. Didier Leconte is a highly experienced investor and Canadian life sciences leader. He has deep commercial experience in Canada and Québec's technology transfer and investment arenas. With a strong dedication to the development of Québec's and Canada's life sciences industries, Didier served as Vice-president, Life Science & Technology for Investissement Quebec and Vice-president Life Sciences at Fonds de solidarité FTQ. Mr. Leconte holds a MBA, Technology Management & Innovation from the Université du Québec à Montréal, a certification in governance from Université Laval and an engineering degree in Material Sciences from École d'ingénieurs Sup Galilée, Institut Galilée, Université Sorbonne Paris Nord.
공시 • Jun 09Valeo Pharma Inc. to Report Q2, 2023 Results on Jun 13, 2023Valeo Pharma Inc. announced that they will report Q2, 2023 results After-Market on Jun 13, 2023
공시 • Feb 08Valeo Pharma Obtains Public Reimbursement for Onstryv in QuebecValeo Pharma Inc. announced that Onstryv (safinamide) for the treatment of patients suffering from Parkinson's disease, is now listed for public reimbursement on the Public Prescription Drug Insurance Plan of the Quebec Régie de l'assurance maladie du Québec ("RAMQ"), effective February 1, 2023. Onstryv® is approved by Health Canada as an add-on therapy to a regimen that includes levodopa for the treatment of the signs and symptoms of idiopathic Parkinson's Disease in patients experiencing "off" episodes. Onstryvâ is a prescription medication available at pharmacies across Canada in 50mg and 100mg tablets. Parkinson's Disease is a progressive neurological disease involving the loss of dopamine producing neurons in the brain. While tremors are the best known symptom, Parkinson's Disease also causes other symptoms including slowed movement, rigid muscles, impaired posture and balance, speech and writing difficulties. On a per capita basis, Canada has amongst the higher incidences of Parkinson's Disease in the world and the number of patients is expected to grow significantly over the next thirty years as the median population age increases. Safinamide, known as Onstryv® in Canada and Xadago® in the rest of the world, is a chemical entity with a unique mode of action including selective and reversible MAO-B inhibition. Clinical trials have established its efficacy in controlling motor symptoms and motor complications in the short term, maintaining this effect over 2 years. Results from 24 month double-blind controlled studies suggest that safinamide shows statistically significant effects on motor fluctuations (ON/OFF time) without increasing the risk of developing troublesome dyskinesia. Onstryv® is a once-daily dose and has no diet restrictions due to its high MAO-B/MAO-A selectivity.
공시 • Jan 27Valeo Pharma Announces Filing of New Drug Submission-Covid 19 with Health Canada for Sabizabulin for the Treatment of Hospitalized Covid-19 PatientsValeo Pharma Inc. announced that Health Canada has accepted for review Veru's New Drug Submission ("NDS-CV") for sabizabulin for COVID-19. Sabizabulin is a novel dual antiviral and anti-inflammatory agent being developed for the treatment of hospitalized moderate to severe COVID-19 adult patients at high risk for acute respiratory distress syndrome (ARDS) and death. The Phase 3 COVID-19 clinical trial of sabizabulin was a double-blind, randomized, placebo controlled trial conducted in 204 hospitalized COVID-19 patients with moderate to severe COVID-19 (= WHO 4-supplemental oxygen) at high risk for ARDS and death. The primary endpoint was the proportion of deaths by Day 60. Patients in both treatment groups were allowed to receive standard of care treatment, including remdesivir, dexamethasone, anti-IL6 receptor antibodies and JAK inhibitors. Based on a planned interim analysis of the first 150 patients randomized, the Independent Data Monitoring Committee unanimously recommended to halt the study early for clear clinical efficacy and no safety concerns were identified. Treatment with sabizabulin 9 mg once daily, an oral, first-in-class, new chemical entity, microtubule disruptor that has dual anti-inflammatory and antiviral properties, resulted in a clinically meaningful and statistically significant 55.2% relative reduction in deaths compared to placebo. The results of the interim analysis were published in The New England Journal of Medicine (NEJM) Evidence. In the final analysis of all 204 patients, sabizabulin demonstrated a statistically significant 51.6% relative reduction in deaths compared to placebo. Sabizabulin was well tolerated. Valeo previously announced in September 2022 that Veru and Valeo had entered into an agreement under which Valeo is the commercial partner for Veru's product candidate sabizabulin for COVID-19 in Canada.
공시 • Jan 26Valeo Pharma Inc. to Report Q4, 2022 Results on Jan 30, 2023Valeo Pharma Inc. announced that they will report Q4, 2022 results at 4:00 PM, US Eastern Standard Time on Jan 30, 2023